This information regarding Naltrexone is being presented here because of its potential importance to seriously ill individuals and its record of safety.
Naltrexone is usually used in 50mg doses as a drug to help heroin or opium addicts, by blocking the effect of such drugs. FDA-approved naltrexone, in a low dose (only 3mg), can boost the immune system, helping those with HIV/AIDS, cancer, and autoimmune diseases. LDN is currently under experimental use for many conditions. Preliminary results are very encouraging: Naltrexone increases the body's production of the beta and metenkephalin endorphins and blood tests have indicated that it can double or even triple the activity of natural killer cells. The web site that presents the current available information on this therapy can be accessed by clicking here.
The following diseases have been benefited by LDN use according to Dr. Bernard Bihari, MD.:
The brief blockade of opioid (endorphin) receptors that is caused by taking LDN at bedtime each night is believed to produce a prolonged improvement in vital elements of the immune system by causing an increase in endorphin production. Normal volunteers who have taken LDN in this fashion have been found to have much higher levels of beta-endorphins circulating in their blood in the following days.
The treatment seems to work by causing the body to secrete endorphins (metenkephalin and beta-endorphin) which attach to cancers having opiate receptors, shrinking the tumors and inhibiting their growth. When metenkephalin and/or beta-endorphins are attached to cancer cells while they are dividing, it seems to stimulate a process of programmed cell death or apoptosis, thus killing some cancer cells. In addition, it is believed that the endorphins act to increase natural killer cells and other healthy immune defenses against cancer.
Dr. Bihari, MD has found that the treatment does not seem to work for prostate cancer patients who have received or are receiving some form of hormone manipulation treatment prior to starting the low dose naltrexone. This includes patients who have received Lupron, Casodex, Eulexin, DES, or other drugs designed to reduce testosterone. In addition, patients who have been treated with PC Spes, the herbal preparation with estrogenic effects, also do not seem to respond.
CLL is one of the cancers that may respond to LDN.
The presence of opioid receptors on tumor cells is considered necessary for low dose naltrexone to be beneficial. Glioblastomas and astrocytomas were thought to be low in these receptors, but this assumption has turned out to be inaccurate. These tumor types contain sizable numbers of opioid receptors on their cell membranes.
Dr. Bihari reports some success using LDN on ovarian cancers.